Comparison of Immune Response Assessment in Colon Cancer by Immunoscore (Automated Digital Pathology) and Pathologist Visual Scoring

Simple Summary The immune response to colon cancer (CC) is highly variable among patients and is clinically relevant. In this study, we compared the immune response assessment for early-stage CC, as measured by Immunoscore (IS), to pathologist visual scoring of the CD3+ and CD8+ T-cell densities at the tumor site (T-score). The objectives were to determine the inter-observer agreement between pathologists and the concordance between the two methods. Agreement between pathologists was minimal to weak. Moreover, a weak concordance between the two methods was observed, leading to misclassification of 48% of cases by pathologist scoring. Due to the high level of immune infiltrate heterogeneity resulting in disagreement of interpretation among pathologists, IS is unlikely to be reproduced via non-standardized methods. Abstract Adjunction of immune response into the TNM classification system improves the prediction of colon cancer (CC) prognosis. However, immune response measurements have not been used as robust biomarkers of pathology in clinical practice until the introduction of Immunoscore (IS), a standardized assay based on automated artificial intelligence assisted digital pathology. The strong prognostic impact of the immune response, as assessed by IS, has been widely validated and IS can help to refine treatment decision making in early CC. In this study, we compared pathologist visual scoring to IS. Four pathologists evaluated tumor specimens from 50 early-stage CC patients and classified the CD3+ and CD8+ T-cell densities at the tumor site (T-score) into 2 (High/Low) categories. Individual and overall pathologist scoring of immune response (before and after training for immune response assessment) were compared to the reference IS (High/Low). Pathologists’ disagreement with the reference IS was observed in almost half of the cases (48%) and training only slightly improved the accuracy of pathologists’ classification. Agreement among pathologists was minimal with a Kappa of 0.34 and 0.57 before and after training, respectively. The standardized IS assay outperformed expert pathologist assessment in the clinical setting.

[1]  E. Oki,et al.  Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  F. Marincola,et al.  Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Labianca,et al.  Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Yong Zhou,et al.  The prognostic value of Immunoscore in patients with cancer: A pooled analysis of 10,328 patients , 2020, The International journal of biological markers.

[5]  J. Galon,et al.  Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer , 2020, Journal for immunotherapy of cancer.

[6]  P. Laurent-Puig,et al.  Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  A. Benson,et al.  Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer , 2020, JNCI cancer spectrum.

[8]  P. Gibbs,et al.  Tumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous differentiation , 2020, Modern Pathology.

[9]  P. Laurent-Puig,et al.  The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions , 2020, Oncoimmunology.

[10]  J. Galon,et al.  Usefulness and robustness of Immunoscore for personalized management of cancer patients , 2020, Oncoimmunology.

[11]  Ahmedin Jemal,et al.  Cancer treatment and survivorship statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[12]  J. Barrett,et al.  The Immunoscore: Colon Cancer and Beyond , 2019, Clinical Cancer Research.

[13]  F. Marincola,et al.  Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided. , 2019, Journal of Clinical Oncology.

[14]  F. Marincola,et al.  International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study , 2018, The Lancet.

[15]  R. Jorissen,et al.  Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes , 2018, Gut.

[16]  P. Laurent-Puig,et al.  Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. , 2017, European journal of cancer.

[17]  G. Wang,et al.  Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis , 2014, British Journal of Cancer.

[18]  F. Marincola,et al.  Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.

[19]  F. Marincola,et al.  Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.

[20]  M. McHugh Interrater reliability: the kappa statistic , 2012, Biochemia medica.

[21]  D. McMillan,et al.  The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. , 2012, Cancer treatment reviews.

[22]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[23]  J. Galon,et al.  The prognostic impact of anti-cancer immune response: a novel classification of cancer patients , 2011, Seminars in Immunopathology.

[24]  S. Yun,et al.  Clinical impact of tumor‐infiltrating lymphocytes for survival in stage II colon cancer , 2010, Cancer.

[25]  L. Sobin,et al.  Digestive System Tumours , 2010 .

[26]  Zlatko Trajanoski,et al.  In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Galon,et al.  The essential role of the in situ immune reaction in human colorectal cancer , 2008, Journal of leukocyte biology.

[28]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[29]  D. McMillan,et al.  The clinical utility of the local inflammatory response in colorectal cancer. , 2014, European journal of cancer.